Dr. Anita Lyn Sabichi

Sabichi is involved in experimental therapeutics of lung, head and neck cancers. She helped investigate a clinical trial involving bevacizumab in the treatment of head and neck cancers. Bevacizumab, also known by brand name Avastin, was recently added to the National Comprehensive Cancer Network’s first-line mesothelioma treatment recommendations.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Get Connected Now

Sabichi, who has been in practice for more than 20 years, graduated from the University of Colorado School of Medicine. She completed her residency at New York Presbyterian Hospital and her fellowship at the National Institutes of Health Clinical Center.

In 2021, Dr. Sabichi published a research study on anti-PD-1 monotherapy, outlining the clinical benefits as first-line therapy for malignant pleural mesothelioma patients.